Dexcom (DXCM) Stock Forecast & Price Target

Compare

4,364 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DXCM Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$85.84

▲(28.20% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $85.84 with a high forecast of $112.00 and a low forecast of $68.00. The average price target represents a 28.20% change from the last price of $66.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","71":"$71","85":"$85","99":"$99","113":"$113"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$68.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,71,85,99,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.52,67.24923076923078,70.97846153846154,74.70769230769231,78.43692307692308,82.16615384615385,85.89538461538461,89.6246153846154,93.35384615384615,97.08307692307693,100.81230769230768,104.54153846153847,108.27076923076923,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.52,65.23692307692308,66.95384615384616,68.67076923076924,70.3876923076923,72.10461538461539,73.82153846153847,75.53846153846155,77.25538461538461,78.9723076923077,80.68923076923078,82.40615384615384,84.12307692307692,{"y":85.84,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.52,63.86461538461539,64.20923076923077,64.55384615384615,64.89846153846155,65.24307692307693,65.58769230769231,65.93230769230769,66.27692307692308,66.62153846153846,66.96615384615384,67.31076923076922,67.65538461538462,{"y":68,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":79.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$112.00

Average Price Target$85.84

Lowest Price Target$68.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanne Wuensch

Citi

$75→$77

Buy

14.99%

Upside

Reiterated

12/12/25

Citi ups DexCom target, adds 'upside 90-day catalyst watch'Citi ups DexCom target, adds 'upside 90-day catalyst watch'

Patrick Wood

Morgan Stanley

$63→$75

Buy

12.01%

Upside

Upgraded

12/02/25

DexCom upgraded to Overweight from Equal Weight at Morgan StanleyDexCom upgraded to Overweight from Equal Weight at Morgan Stanley

Matthew O'Brien

Piper Sandler

$75

Buy

12.01%

Upside

Reiterated

12/02/25

Dexcom (DXCM) Gets a Buy from Piper Sandler

Daniel Markowitz CFA

Evercore ISI

$68

Hold

1.55%

Upside

Initiated

11/26/25

DexCom initiated with an In Line at Evercore ISIDexCom initiated with an In Line at Evercore ISI

Travis Steed

Bank of America Securities

$100

Buy

49.34%

Upside

Reiterated

11/25/25

Bank of America Securities Sticks to Their Buy Rating for Dexcom (DXCM)

Steven Silver

Argus Research

$100→$90

Buy

34.41%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM) and DENTSPLY SIRONA (NASDAQ: XRAY)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/07/25

Dexcom: A Compelling Buy Amid Operational Improvements and Market OpportunitiesWe believe this can give incremental confidence in management’s commentary from the quarter that the most recent reliability issues have been resolved and are behind it.

Richard Newitter

Truist Financial

$94→$82

Buy

22.46%

Upside

Reiterated

11/03/25

DexCom price target lowered to $82 from $94 at TruistDexCom price target lowered to $82 from $94 at Truist

Matt Miksic

Barclays

$98→$80

Hold

19.47%

Upside

Reiterated

11/03/25

DexCom price target lowered to $80 from $98 at BarclaysDexCom price target lowered to $80 from $98 at Barclays

Danielle Antalffy

UBS

$106→$95

Buy

41.88%

Upside

Reiterated

11/03/25

DexCom price target lowered to $95 from $106 at UBSDexCom price target lowered to $95 from $106 at UBS

Matthew Taylor

Jefferies

$112

Buy

67.26%

Upside

Reiterated

10/31/25

Dexcom (DXCM) Gets a Buy from Jefferies

Jeff Johnson

Robert W. Baird

$90→$82

Buy

22.46%

Upside

Reiterated

10/31/25

DexCom price target lowered to $82 from $90 at BairdDexCom price target lowered to $82 from $90 at Baird

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

10/31/25

Oppenheimer Remains a Hold on Dexcom (DXCM)

Robbie Marcus

J.P. Morgan

$90→$75

Hold

12.01%

Upside

Reiterated

10/31/25

DexCom price target lowered to $75 from $90 at JPMorganDexCom price target lowered to $75 from $90 at JPMorgan

Jonathan Block

Stifel Nicolaus

$85

Buy

26.94%

Upside

Reiterated

10/31/25

Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanne Wuensch

Citi

$75→$77

Buy

14.99%

Upside

Reiterated

12/12/25

Citi ups DexCom target, adds 'upside 90-day catalyst watch'Citi ups DexCom target, adds 'upside 90-day catalyst watch'

Patrick Wood

Morgan Stanley

$63→$75

Buy

12.01%

Upside

Upgraded

12/02/25

DexCom upgraded to Overweight from Equal Weight at Morgan StanleyDexCom upgraded to Overweight from Equal Weight at Morgan Stanley

Matthew O'Brien

Piper Sandler

$75

Buy

12.01%

Upside

Reiterated

12/02/25

Dexcom (DXCM) Gets a Buy from Piper Sandler

Daniel Markowitz CFA

Evercore ISI

$68

Hold

1.55%

Upside

Initiated

11/26/25

DexCom initiated with an In Line at Evercore ISIDexCom initiated with an In Line at Evercore ISI

Travis Steed

Bank of America Securities

$100

Buy

49.34%

Upside

Reiterated

11/25/25

Bank of America Securities Sticks to Their Buy Rating for Dexcom (DXCM)

Steven Silver

Argus Research

$100→$90

Buy

34.41%

Upside

Reiterated

11/07/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM) and DENTSPLY SIRONA (NASDAQ: XRAY)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

11/07/25

Richard Newitter

Truist Financial

$94→$82

Buy

22.46%

Upside

Reiterated

11/03/25

DexCom price target lowered to $82 from $94 at TruistDexCom price target lowered to $82 from $94 at Truist

Matt Miksic

Barclays

$98→$80

Hold

19.47%

Upside

Reiterated

11/03/25

DexCom price target lowered to $80 from $98 at BarclaysDexCom price target lowered to $80 from $98 at Barclays

Danielle Antalffy

UBS

$106→$95

Buy

41.88%

Upside

Reiterated

11/03/25

DexCom price target lowered to $95 from $106 at UBSDexCom price target lowered to $95 from $106 at UBS

Matthew Taylor

Jefferies

$112

Buy

67.26%

Upside

Reiterated

10/31/25

Dexcom (DXCM) Gets a Buy from Jefferies

Jeff Johnson

Robert W. Baird

$90→$82

Buy

22.46%

Upside

Reiterated

10/31/25

DexCom price target lowered to $82 from $90 at BairdDexCom price target lowered to $82 from $90 at Baird

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

10/31/25

Oppenheimer Remains a Hold on Dexcom (DXCM)

Robbie Marcus

J.P. Morgan

$90→$75

Hold

12.01%

Upside

Reiterated

10/31/25

DexCom price target lowered to $75 from $90 at JPMorganDexCom price target lowered to $75 from $90 at JPMorgan

Jonathan Block

Stifel Nicolaus

$85

Buy

26.94%

Upside

Reiterated

10/31/25

Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

1 Month

xxx

Success Rate

14/25 ratings generated profit

Average Return

+2.96%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +2.96% per trade.

3 Months

xxx

Success Rate

26/39 ratings generated profit

Average Return

+10.25%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +10.25% per trade.

1 Year

Joanne WuenschCiti

Success Rate

20/35 ratings generated profit

Average Return

+11.24%

reiterated a buy rating 2 days ago

Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +11.24% per trade.

2 Years

xxx

Success Rate

19/33 ratings generated profit

Average Return

+26.44%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.58% of your transactions generating a profit, with an average return of +26.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DXCM has received 33 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. DXCM average Analyst price target in the past 3 months is 85.84.

Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $0.65 with a range of $0.59 to $0.69. The previous quarter’s EPS was $0.61. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $1.24B with a range of $1.22B to $1.25B. The previous quarter’s sales results were $1.21B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Stock Forecast FAQ

What is DXCM’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 85.84.

What is DXCM’s upside potential, based on the analysts’ average price target?

Dexcom has 28.20% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DXCM a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Dexcom’s price target?

The average price target for Dexcom is 85.84. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $112.00 ,the lowest forecast is $68.00. The average price target represents 28.20% Increase from the current price of $66.96.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of DXCM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Dexcom (DXCM) Stock Forecast & Price Target

DXCM Analyst Ratings

DXCM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

DXCM Analyst Recommendation Trends

DXCM Financial Forecast

DXCM Earnings Forecast

DXCM Sales Forecast

DXCM Stock Forecast FAQ

Detailed List of Analyst Forecasts